18 pounds off in three months! "GIP/GLP-1/glucagon Tri-Receptor Agonist" Achieves Dual Benefits of Hypoglycemic Weight Loss 2022EASD

Introduction: The "new triptych" of the hypoglycemic world? "GIP/GLP-1/glucagon trireceptor agonist" achieves double benefits of
hypoglycemic weight loss.

From September 19 to 23, 2022, the international conference in the field of endocrinology "2022 European Association for Diabetes Research Annual Conference" was held
in Stockholm, Sweden in the form of "online + offline".

At the meeting, scholars shared a study entitled "A novel triple GIP/GLP-1/glucagon agonist Ly3437943(LY) can reduce blood glucose and weight in patients with type 2 diabetes after 12 weeks of treatment
".

What is the efficacy and safety of triple agonist LY?

Multireceptor insulin agonists
for the treatment of several metabolic disorders are currently under development.

LY is an in-research triplet agonist with potent activity
against glucose-dependent insulin polypeptides (GIP), glucagon-like peptide-1GLP-1) and glucagon receptors.

LY has been studied safely in previous first human trials, and the pharmacokinetic properties support weekly administration
.

The primary objective of this randomized, double-blind, placebo-controlled, Phase 1 proof-of-concept study was to assess the safety and tolerance of multiple doses of LY in patients with type 2 diabetes mellitus
(T2D).

Seventy-two patients were randomly assigned (9:3:1) to 5 increased doses of LY subcutaneous injection group, placebo group, and dulaglutide 1.
5 mg group
, respectively.

In the cohort, dose increments are implemented in up to 2 cohorts
.

Vital signs, laboratory data, and adverse events (AEs) are monitored to assess safety and tolerability
.

Efficacy
is assessed by monitoring changes in glycosylated hemoglobin (HbA1c) and body weight at week 12.

Weight loss of 18 pounds in March, "triple receptor agonist" to achieve sugar reduction, weight loss double benefit!

1.
LY effectiveness

1.
By week 12, the mean systolic and diastolic blood pressure in the LY group decreased from baseline compared to the placebo group; In most LY cohorts and dulaglutide cohorts, pulse and heart rate increased from baseline, but there was no significant change in
the placebo group.

By week 12, the mean HbA1c in all groups decreased from baseline, and the higher dose LY group showed significant statistical significance, with a placebo-corrected decrease of up to 17.
1 mmol/mol
.

3.
In addition to the initial cohort, the LY group observed a dose-dependent decrease in mean placebo-corrected body weight, up to 8.
96 kg
.

2.
LY security

The most common AEs that appear in treatment are gastrointestinal reactions (nausea and diarrhea), the severity of which is mostly mild
.

Summary of this article

LY3437943 exhibits similar safety and tolerability
to other incretin.

In this study, the efficacy of blood glucose and weight loss expected by LY in the treatment of T2D and obesity was highlighted, with the potential
to provide additional benefits compared to existing treatments.

Introduction of translators

Deng Yujie

Graduated from Ruijin Hospital Affiliated to Shanghai Jiao Tong University, he has been engaged in basic and clinical work
related to endocrine and metabolic diseases.

He presided over the National Natural Science Foundation of China Youth Project, Shandong Natural Science Foundation Youth Project, Qingdao Postdoctoral Applied Research Project, Shandong Geriatrics Association Science and Technology Public Program Project each, published more than 10 SCI articles as corresponding author, first author and co-first author, and applied for 1 international invention patent and 1 national invention patent (both first).


He specializes in the diagnosis and treatment
of diabetes, obesity, osteoporosis, adrenal glands, thyroid and other related diseases.